Table 1 Ongoing clinical trials of combined treatment with blinatumomab for B-ALL
From: Recent advances on blinatumomab for acute lymphoblastic leukemia
NCT Number | Patients | Treatment | Phase |
|---|---|---|---|
NCT02877303 | Newly diagnosed B-ALL | Blinatumomab + hyper-CVAD | Phase 2 |
NCT03367299 | Untreated Ph− CD19+ B-ALL | Blinatumomab + chemotherapy | Phase 2 |
NCT03480438 | Older newly diagnosed Ph/BCR-ABL- CD19+ B-ALL | Blinatumomab + chemotherapy | Phase 2 |
NCT03518112 | Ph−R/R B-ALL | Blinatumomab + chemotherapy | Phase 2 |
NCT03914625 | Newly diagnosed standard risk or down syndrome B-ALL and localized B-Lly | Blinatumomab + chemotherapy | Phase 3 |
NCT02143414 | Older newly diagnosed Ph−B-ALL | Blinatumomab + chemotherapy | Phase 2 |
Older newly diagnosed or R/R Ph+ (Ph-like) B-ALL | Blinatumomab + dasatinib + prednisone | ||
NCT03263572 | Ph/BCR-ABL+ B-ALL | Blinatumomab + ponatinib + cytarabine + Methotrexate | Phase 2 |
NCT03147612 | R/R Ph+/BCR-ABL + B-ALL | Blinatumomab + ponatinib + chemotherapy | Phase 2 |
NCT02744768 | Newly diagnosed adult Ph+ B-ALL | Blinatumomab + dasatinib | Phase 2 |
NCT03605589 | R/R B-ALL | Blinatumomab + pembrolizumab | Phase 1 |
NCT03160079 | R/R B-ALL | Blinatumomab + pembrolizumab | Phase 1/2 |
NCT03512405 | R/R B-ALL | Blinatumomab + pembrolizumab | Phase 1/2 |
NCT02879695 | R/R B-ALL | Blinatumomab + nivolumab with or without ipilimumab | Phase 1 |
NCT02997761 | R/R B-ALL | Blinatumomab + ibrutinib | Phase 2 |
NCT03739814 | Newly diagnosed or R/R CD22+ B-ALL | Blinatumomab + inotuzumab ozogamicin | Phase 2 |
NCT03751709 | R/R CD19+ B-ALL | Blinatumomab + HMCT | Phase 1 |
NCT03849651 | Hematologic malignancies | Blinatumomab + DLI | Phase 2 |
NCT03982992 | B-ALL with MC or MRD-positive after allo-HSCT | Blinatumomab + DLI | Phase 2 |
NCT02790515 | R/R hematologic malignancies | Blinatumomab + haploidentical HCT | Phase 2 |